Fluindione

Summary

Fluindione (CHEMBL24924) is an approved small molecule (ATC B01AA12); indicated across 1 condition including thrombotic disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: B01AA12
• Indications: 1 condition
• Clinical trials: 2
• Chemistry: 240.23 Da · C15H9FO2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL24924
Name	Fluindione
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	68942
ATC	B01AA12
Molecular formula	C15H9FO2
Molecular weight	240.23
InChIKey	NASXCEITKQITLD-UHFFFAOYSA-N

SMILES: C1=CC=C2C(=C1)C(=O)C(C2=O)C3=CC=C(C=C3)F

IUPAC name: 2-(4-fluorophenyl)indene-1,3-dione

Also known as: Fluindiona, Fluindione, Previscan, Previsccan, SID29216219, FLUINDIONE, SID144205432

Patent coverage: 211 distinct patent families (696 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 682 (98%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Polyunsaturated fatty acid 5-lipoxygenase.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P12527	5.02	IC50	9600	nM	CHEMBL_ACT_830234

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
thrombotic disease	4	MONDO:0000831	HP:0004419

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE4	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02161965	PHASE4	COMPLETED	Vascular CalcIfiCation and sTiffness Induced by ORal antIcoAgulation
NCT02286414	Not specified	COMPLETED	Benefit/Risk in Real Life of New Oral Anticoagulants and Vitamin K Antagonists in Patients Aged 80 Years and Over

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

PharmGKB dosing guidelines (1) — CPIC / DPWG genotype-guided dosing for this drug (drug × pharmacogene):

Guideline	Source	Gene(s)	Dosing	Recommendation
Annotation of RNPGx Guideline for acenocoumarol, fluindione, warfarin	RNPGx	CYP2C9;VKORC1	yes	yes

PharmGKB also curates 1 clinical and 11 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).